Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.

@article{BalbirGurman2015LongtermFO,
  title={Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.},
  author={Alexandra Balbir-Gurman and Mordechai Yigla and Ludmila Guralnik and Emilia Hardak and Anna Solomonov and Alexander P Rozin and Kohava Toledano and Amir Dagan and Rema Bishara and Doron Markovits and Menahem A. Nahir and Yolanda Braun-Moscovici},
  journal={The Israel Medical Association journal : IMAJ},
  year={2015},
  volume={17 3},
  pages={150-6}
}
BACKGROUND Scleroderma lung disease (ILD-SSc) is treated mainly with cyclophosphamide (CYC). The effectiveness of CYC was judged after 12-24 months in most reports. OBJECTIVES To analyze the effect of monthly intravenous CYC on pulmonary function tests including forced vital capacity (FVC) and diffusing lung capacity (DLCO), as well as Rodnan skin score (mRSS), during long-term follow-up. METHODS We retrospectively collected the data on 26 ILD-SSc patients who began CYC treatments before… CONTINUE READING
1 Citations
25 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Similar Papers

Loading similar papers…